Mantle cell lymphoma · 6 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Lenalidomide and Rituximab (R2) Variant #08 | — | R 185 508 | 28d | — | ~8.5 mo | ~5 | ~R 297 838 PFS proxy · indirect | 1 |
Bortezomib monotherapy Variant #03 | — | R 6 762 | 21d | ~30.3 mo | — | ~8 | ~R 54 096 PFS proxy · indirect | 5 |
Lenalidomide monotherapy Variant #01 | — | R 2 178 | 28d | — | — | 24 | R 52 272 PFS proxy | 1 |
Rituximab monotherapy Variant #09 Partial | — | — | 28d | — | — | 1 | — | 2 |
Interferon alfa monotherapy Variant #01 Partial | — | — | 7d | — | — | ~2 | — | — |
Observation Partial | — | — | — | — | — | — | — | 1 |
6 of 6 regimens shown